Patients with melanoma and cIRAEs on immune checkpoint inhibitors face higher toxicity risks but improved survival, warranting close monitoring.
The post Cutaneous Immune-Related AEs May Predict Toxicities in Patients Treated With ICI first appeared on Physician’s Weekly.
